On Monday Bicara Therapeutics Inc (NASDAQ: BCAX) opened higher 6.66% from the last session, before settling in for the closing price of $8.71. Price fluctuations for BCAX have ranged from $7.80 to $28.09 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 42.88% at the time writing. With a float of $32.77 million, this company’s outstanding shares have now reached $54.53 million.
Let’s look at the performance matrix of the company that is accounted for 55 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Bicara Therapeutics Inc (BCAX) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Bicara Therapeutics Inc is 39.92%, while institutional ownership is 62.30%. The most recent insider transaction that took place on Jun 16 ’25, was worth 165,096. In this transaction Chief Legal Officer of this company sold 15,829 shares at a rate of $10.43, taking the stock ownership to the 0 shares. Before that another transaction happened on Jun 16 ’25, when Company’s Officer proposed sale 31,658 for $10.84, making the entire transaction worth $343,173.
Bicara Therapeutics Inc (BCAX) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.55 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 42.88% per share during the next fiscal year.
Bicara Therapeutics Inc (NASDAQ: BCAX) Trading Performance Indicators
Check out the current performance indicators for Bicara Therapeutics Inc (BCAX). In the past quarter, the stock posted a quick ratio of 24.62.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.70, a number that is poised to hit -0.54 in the next quarter and is forecasted to reach -2.65 in one year’s time.
Technical Analysis of Bicara Therapeutics Inc (BCAX)
Bicara Therapeutics Inc (NASDAQ: BCAX) saw its 5-day average volume 1.27 million, a positive change from its year-to-date volume of 0.68 million. As of the previous 9 days, the stock’s Stochastic %D was 18.12%.
During the past 100 days, Bicara Therapeutics Inc’s (BCAX) raw stochastic average was set at 16.78%, which indicates a significant decrease from 19.01% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 74.80% in the past 14 days, which was lower than the 120.21% volatility it showed in the past 100 days.
Nevertheless, the first resistance level for the watch stands at $9.61 in the near term. At $9.94, the stock is likely to face the second major resistance level. The third major resistance level sits at $10.46. If the price goes on to break the first support level at $8.77, it is likely to go to the next support level at $8.25. The third support level lies at $7.92 if the price breaches the second support level.
Bicara Therapeutics Inc (NASDAQ: BCAX) Key Stats
There are currently 54,536K shares outstanding in the company with a market cap of 506.64 million. Presently, the company’s annual sales total 0 K according to its annual income of -68,000 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -36,850 K.
